Targeting Vitamin D Deficiency to Limit Exacerbations in Respiratory Diseases: Utopia or Strategy With Potential?
Calcif Tissue Int. 2019 Jul 26. doi: 10.1007/s00223-019-00591-4
Maes K1, Serré J2, Mathyssen C2, Janssens W2, Gayan-Ramirez G2.
1 KU Leuven, Leuven, Belgium. karen.maes at kuleuven.be
2 KU Leuven, Leuven, Belgium.
Breathing category starts with the following
Patients with respiratory diseases such as cystic fibrosis, chronic obstructive pulmonary disease, or asthma often experience an acute worsening of respiratory symptoms, termed exacerbations. Although the course of exacerbations is disease specific, they are mostly triggered by a respiratory infection. Exacerbations often require hospitalization and are an important cause of mortality. Treatments of exacerbations aim to minimize the negative impact and to prevent subsequent events. Despite many existing therapy options, many patients do not benefit from therapy and suffer from recurrent events. Vitamin D deficiency is a worldwide problem and is extremely prevalent in these patients. Vitamin D, known for its calcemic effects, also has immunomodulatory and anti-infectious actions and can therefore be a possible agent to treat or prevent exacerbations. This review will focus on vitamin D as a potential candidate to treat or prevent exacerbations in CF, COPD, and asthma.
|2049 visitors, last modified 26 Nov, 2019,